SAN
DIEGO, May 22, 2023 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused
on developing products to diagnose and treat cancer and life
threatening infectious diseases, today announced that it has
received Ethics Review Board (ERB) approval from the Maulana Azad
Medical College (MAMC), for a second site for its ongoing clinical
trial of Aethlon's Hemopurifier® to treat severe
COVID-19 in India.
MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of
Delhi and is operated by the
Delhi government.
"Cases of COVID-19 infection that require hospitalization
continue to occur in India. The
addition of MAMC as a second high quality clinical site may improve
our enrollment of patients who go on to require ICU care for severe
infection," commented Steven LaRosa,
M.D., Chief Medical Officer of Aethlon Medical.
Aethlon Medical's clinical trial of the Hemopurifier in patients
with SARS-CoV-2, or COVID-19, in
the ICU with severe or life-threatening disease, is designed to
enroll up to 15 patients at up to three centers throughout
India. The initial site for the
ongoing trial is Medanta Medicity Hospital in Gurgaon, India, and currently remains open for
enrollment, with one patient treated to date.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on
developing the Hemopurifier, a clinical stage immunotherapeutic
device which is designed to combat cancer and life-threatening
viral infections. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and harmful
exosomes from blood utilizing its proprietary lectin-based
technology. This action has potential applications in cancer, where
exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA)
designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease. The Hemopurifier also
holds an FDA Breakthrough Device designation and an open
Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with
approved therapies.
Additional information can be found at
www.AethlonMedical.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," "potentially" or similar
expressions constitute forward-looking statements. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. These
forward-looking statements are based upon Aethlon's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to
enroll patients in its clinical trials in India, the Company's ability to obtain FDA
approval of its new GNA supplier in a timely manner, the Company's
ability to successfully treat patients under any Emergency Use
pathway, the Company's ability to successfully complete development
of its Hemopurifier, the Company's ability to raise additional
funds, and the Company's ability expand its clinical trials into
other areas of cancer, and other potential risks. The foregoing
list of risks and uncertainties is illustrative but is not
exhaustive. Additional factors that could cause results to differ
materially from those anticipated in forward-looking statements can
be found under the caption "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended March
31, 2022, and in the Company's other filings with the
Securities and Exchange Commission, including its quarterly Reports
on Form 10-Q. All forward-looking statements contained in this
press release speak only as of the date on which they were made.
Except as may be required by law, the Company does not intend, nor
does it undertake any duty, to update this information to reflect
future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-receives-ethics-board-approval-to-add-second-site-to-its-ongoing-clinical-trial-of-its-hemopurifier-to-treat-severe-covid-19-in-india-301830177.html
SOURCE Aethlon Medical, Inc.